Volume 14 Supplement 20
Annual Academy of Sickle Cell and Thalassaemia (ASCAT) Conference: A Summary of the Proceedings
Publication costs for this supplement are supported by grant funding from Novartis, BlueBird Bio, Nova Laboratories Ltd, Global Blood Therapeutics, Celgene, Cyclerion, AstraZeneca, AddMedica, TerumboBCT, Crispr Therapeutics, Agios, Resonant Health, and Evelina Children’s Hospital and Guy’s and St. Thomas NHS trust hospital. Dr. Campbell receives research funding and consultancy from Global Blood Therapeutics (GBT), Novartis and Bluebird Bio. B Andemariam does consultancy for Bluebird Bio, CRISPR/Vertex, Novartis, NovoNordisk, Roche, Cyclerion, Terumo, Sanofi and serves on the DSMB for Global Blood Therapeutics and receives research funding from Imara. Dr. Inusa receives education funding from Novartis, AstraZeneca, Global Blood Therapeutics, Celgene and Vertex. Dr. Strunk is a consultant for Novartis and speaks for Global Blood Therapeutics and Medunik USA. Dr. Colombatti receives research funding from Global Blood Therapeutics and Novartis. All other Supplement Editors report no competing interests. The article has undergone the journal's standard peer review process for supplements.
London, UK21-23 October 2019
Edited by Crawford J. Strunk, Andrew Campbell, Biree Andemariam, Raffaella Colombatti, Marsha Treadwell, Rachel Kesse-Adu and Baba PD Inusa.
The fourteenth annual ASCAT conference was held 21–23 October 2019. The theme of the conference was ‘Sickle Cell and Thalassaemia disorders new treatment horizon; while ensuring patient safety and delivering e...